Tissue Engineering for Diabetes Treatment

Chinese researchers reported the first case of a Type 1 diabetes patient achieving insulin independence within 75 days of receiving chemically induced pluripotent stem cell-derived islets—after 11 years of complete insulin dependence . A second patient with 25-year Type 2 diabetes achieved the same outcome in 11 weeks. These aren't marginal improvements. These are functional cures: HbA1c dropping from diabetic to normal ranges, time-in-target glucose rising from 43% to 98%, patients eating freely without calculating carbohydrates . The mechanism is precise. Scientists reprogram the patient's own cells chemically—avoiding genetic modification risks—guide them to become glucose-responsive beta cells, and transplant them where they can be monitored and retrieved if needed . Vertex Pharmaceuticals has replicated similar results in 37 patients using comparable stem cell approaches. But precision demands patience. Three patients in China. Dozens globally. Follow-up measured in months, not decades. Regenerative medicine has crossed a threshold. What was theoretically impossible—rebuilding destroyed insulin production—is now demonstrated reality. The science is accelerating. The verification must keep pace. Sources: : Wang et al. (2024). "Transplantation of Chemically Induced Pluripotent Stem-Cell-Derived Islets Under the Abdominal Anterior Rectus Sheath." Cell. https://lnkd.in/dpYAJj_D, https://lnkd.in/dgBquMWJ : Peking University / Tianjin First Central Hospital press release, September 2024. Patient achieved insulin independence at 75 days post-transplant. https://lnkd.in/duHpRgtb : Cell Discovery (2024). Second case report: 59-year-old male with Type 2 diabetes, 25-year duration, insulin-free at 11 weeks. https://lnkd.in/dbMG2vZF : FDA briefing documents on stem cell-derived islet therapies (2024). Risks include tumorigenicity, immune rejection, and graft longevity. https://lnkd.in/dG3iBGEJ : Vertex Pharmaceuticals (2024). Phase 1/2 VX-880 trial data: 37 patients with Type 1 diabetes showed improved glycemic control and reduced insulin requirements. https://lnkd.in/dFDS_g5g Image Source : https://lnkd.in/dWy7sQiB

A 25-year-old woman from Tianjin has become the FIRST person with type 1 diabetes to regain insulin production after receiving a transplant of lab-grown cells derived from her own body. 🔬 𝐑𝐞𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐦𝐢𝐧𝐠 𝐂𝐞𝐥𝐥𝐬 𝐭𝐨 𝐏𝐫𝐨𝐝𝐮𝐜𝐞 𝐈𝐧𝐬𝐮𝐥𝐢𝐧 - What Happened? Scientists extracted cells from the woman and reprogrammed them into induced pluripotent stem (iPS) cells. These are cells that can develop into almost any type of cell in the body. - How Did They Do It Differently? Instead of using traditional methods that introduce specific proteins to trigger this change, the team used small molecules to guide the cells back to a pluripotent state. This approach offers more control over the process. - Creating Insulin-Producing Cells: The iPS cells were then developed into clusters of insulin-producing islet cells, similar to those found in a healthy pancreas. 💉 𝐓𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 - New Transplant Site: The islet cells were injected into her abdominal muscles rather than the liver, allowing doctors to monitor them more easily. - Outcome: Just two and a half months post-transplant, she began producing enough insulin on her own and no longer needed injections. Her blood glucose levels stabilized, remaining within the target range over 98% of the time. - Quality of Life Improvement: She can now enjoy foods without strict dietary restrictions, significantly enhancing her daily life. 🌐 𝐖𝐡𝐲 𝐓𝐡𝐢𝐬 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 This treatment could offer a new avenue for the millions affected by Type 1 diabetes worldwide. It may decrease the reliance on donor organs and long-term use of immunosuppressive drugs, which have significant side effects. Since Type 1 diabetes is an autoimmune condition where the body attacks its own cells, this method might pave the way for treating other similar diseases. 🧪 𝐄𝐱𝐩𝐞𝐫𝐭 𝐎𝐩𝐢𝐧𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐍𝐞𝐱𝐭 𝐒𝐭𝐞𝐩𝐬 James Shapiro, a transplant surgeon and researcher, described the outcome as "stunning," emphasizing the potential impact on diabetes treatment. While the results are promising, more studies with additional participants are planned to verify the treatment's effectiveness and safety over the long term. Researchers need to ensure that the new cells won't be attacked by the patient's immune system and that the effects are lasting. Do you believe reprogrammed stem cells could be the key to treating autoimmune diseases like Type 1 diabetes? #innovation #technology #future #management #startups

A groundbreaking clinical trial by Vertex Pharmaceuticals has demonstrated that a stem cell–derived therapy called zimislecel (previously VX-880) enabled 10 out of 12 patients with severe type 1 diabetes to completely stop using insulin. These patients had a history of life-threatening low blood sugar and were entirely dependent on insulin before the trial. The therapy works by infusing stem cell–derived islet cells into the liver through the portal vein, allowing the body to naturally produce insulin. All 12 patients in the trial showed restored insulin production, with an average 92% reduction in daily insulin needs, and most achieved near-normal blood glucose levels without hypoglycemic episodes. The results were presented at the American Diabetes Association’s 2024 Scientific Sessions and published in the New England Journal of Medicine. The trial represents a major step toward a functional cure for type 1 diabetes. However, it’s not without risks. To prevent immune rejection of the implanted cells, recipients must take lifelong immunosuppressive drugs, which can cause serious side effects, including infections and increased cancer risk. This limits the therapy’s immediate applicability to the broader population. Additionally, this was a small Phase 1/2 trial, so larger studies are needed to validate the results, determine long-term safety, and possibly find ways to avoid immunosuppression—like using gene-edited or encapsulated cells. Despite these limitations, the success of zimislecel is considered a historic milestone in regenerative medicine. One notable case involved a 36-year-old woman who remained insulin-free nearly two years after treatment. Researchers are now working on further trials to optimize the therapy and make it more widely accessible, potentially changing the future of diabetes care for millions.

Chinese researchers reported the first case of a Type 1 diabetes patient achieving insulin independence within 75 days of receiving chemically induced pluripotent stem cell-derived islets—after 11 years of complete insulin dependence . A second patient with 25-year Type 2 diabetes achieved the same outcome in 11 weeks. These aren't marginal improvements. These are functional cures: HbA1c dropping from diabetic to normal ranges, time-in-target glucose rising from 43% to 98%, patients eating freely without calculating carbohydrates . The mechanism is precise. Scientists reprogram the patient's own cells chemically—avoiding genetic modification risks—guide them to become glucose-responsive beta cells, and transplant them where they can be monitored and retrieved if needed . Vertex Pharmaceuticals has replicated similar results in 37 patients using comparable stem cell approaches. But precision demands patience. Three patients in China. Dozens globally. Follow-up measured in months, not decades. Regenerative medicine has crossed a threshold. What was theoretically impossible—rebuilding destroyed insulin production—is now demonstrated reality. The science is accelerating. The verification must keep pace.

Imagine never needing another insulin injection again. That future might be closer than you think. Scientists have just created something that sounds like pure science fiction, but it's happening in labs right now. 3D printed pancreas cells that could free millions from the daily burden of managing Type 1 diabetes. This isn't just another treatment, it's a potential cure. ---------- The breakthrough works by using bioprinting technology to create functional pancreatic beta cells, the exact cells that Type 1 diabetes destroys. These aren't just any cells though. They're engineered with incredible precision to survive in the body and respond to blood sugar changes in real time, just like a healthy pancreas would. Researchers at institutions including NVIDIA's BioNeMo platform and various universities have been perfecting the technique of printing living tissue that can be safely implanted. The cells are encapsulated in a protective bioink material that shields them from immune system attacks while still allowing glucose to enter and insulin to exit. Early animal trials have shown the implants can maintain stable blood sugar levels for months without rejection. What makes this truly revolutionary is that it addresses the root cause rather than just managing symptoms. Current insulin therapy requires constant vigilance, calculating carbs, timing injections, and still dealing with dangerous blood sugar swings. This implant would work automatically, 24/7, responding to your body's needs without any conscious effort. Researchers estimate that if current trials continue showing positive results, human clinical trials could expand significantly within the next 3 to 5 years. The implications extend beyond diabetes too. Success with 3D printed pancreatic cells could pave the way for printing other organs and tissues, potentially solving the global organ shortage crisis. For now, the 43 million people worldwide living with Type 1 diabetes are watching closely, hopeful that freedom from injections is finally within reach. Sources: Nature Biotechnology journal studies on bioprinted islet cells, research from institutions working on diabetes cell therapy including work highlighted in medical technology publications covering 3D bioprinting advances in 2023-2024.

A remarkable medical breakthrough is reshaping our understanding of Type 1 diabetes treatment. Researchers in China have achieved the first documented long-term insulin independence in a 25-year-old woman with Type 1 diabetes by utilizing her own reprogrammed stem cells. This treatment represents a significant advancement toward regenerative therapies that aim to restore lost biological function. Type 1 diabetes occurs when the immune system destroys insulin-producing beta cells in the pancreas, leading patients to rely on insulin injections for life. In this breakthrough, scientists reprogrammed the patient’s blood cells into stem cells and developed them into insulin-producing islet-like cells. After transplantation, these cells began to function like natural pancreatic cells, effectively sensing blood sugar levels and releasing insulin. Months later, the patient no longer required insulin injections and maintained healthy glucose control. Researchers refer to this as sustained remission, as the patient still needs immune-suppressing medication. The implications of this breakthrough are profound: - No donor needed - No insulin injections - Regeneration of lost function using the patient’s own biology If this success can be replicated in larger trials, stem cell therapy could fundamentally transform treatment for millions of individuals living with Type 1 diabetes worldwide. This achievement is not a miracle or luck; it is a milestone built on decades of scientific persistence. Study: Cell Discovery (Nature Research) https://lnkd.in/eWq5e_jC #MedicalBreakthrough #StemCellTherapy #DiabetesResearch #RegenerativeMedicine #HealthcareInnovation #Biotech #ScienceNews #Hope #FutureOfMedicine #Endocrinology #GlobalHealth #ResearchMatters

French researchers regenerated beta cells that produce insulin naturally once again now. Your pancreas contains about one million beta cells that produce insulin—and most type 2 diabetics lose 50% of them before symptoms appear. French scientists at INSERM discovered how to reverse this loss by reactivating dormant beta cells hiding within pancreatic tissue. Using a combination of growth factors and immune-regulating drugs, they triggered regeneration of new beta cells and restored function in existing cells that had stopped producing insulin. The research centers on a surprising discovery: beta cell loss in diabetes isn't purely death—many cells enter a dormant state, essentially hibernating. These sleeping cells retain their identity and capacity to function, they just need the right signal to wake up. Scientists identified that blocking a specific inflammatory pathway while providing growth factors causes dormant cells to reactivate and begin producing insulin again. In animal studies, this approach restored glucose control despite pre-existing 70% beta cell loss. The mechanism involves redirecting immune cells that normally attack beta cells in type 1 diabetes into a supportive role. Instead of eliminating beta cells, these immune cells help create an environment supporting beta cell proliferation and reactivation. It's a complete flip from the standard autoimmune paradigm—instead of suppressing the immune system globally, scientists are reprogramming it to become a healing force. Early human trials show remarkable promise. Patients receiving the treatment showed new C-peptide production—the marker that beta cells are actively producing insulin. Glucose control improved measurably within weeks, with improvement continuing over months. If this scales to larger populations, diabetes treatment fundamentally changes from lifelong insulin injection to a time-limited therapy potentially curing the disease. The implications for improving millions of lives globally are almost incomprehensible. Source: INSERM Paris, Cell Reports 2025

🧬🖨️ Bioprinting a functional pancreas to fight diabetes — and it's working. @Rousselot, a 130-year-old collagen biomaterials company, is proving that deep materials science expertise is a critical and often overlooked enabler of the bioprinting revolution. Their latest milestone comes through the EU-backed ENLIGHT project: a pan-European consortium with a bold goal of bioprinting a functional pancreatic model to transform how we discover and test diabetes drugs. Key technologies & breakthroughs: 🔬 Gelatin-based bioinks (X-Pure®) — Rousselot developed a hydrogel with tunable mechanical properties to recreate the pancreatic microenvironment, creating a "library" of gelatins and GelMA variants, including a single-component suspension medium that supports extrusion inside a volumetric printing bath — without temperature control — remaining stable for several hours ⚡ Volumetric bioprinting — unlike conventional 3D printers, which take an hour, this volumetric bioprinter produces results within a minute — critical because cell survival rates decrease rapidly over time 🧫 Living tissue that lasts — the ENLIGHT researchers successfully bioprinted pancreatic cell-laden gels that remained viable over 21 days of culture 🧪 iPSC-powered personalization — the ultimate goal involves using a patient's own induced pluripotent stem cells (iPSCs) to build patient-specific tissue for precision drug testing The ENLIGHT consortium includes UMC Utrecht, ETH Zürich, EPFL, AstraZeneca, University of Naples Federico II, and bioprinting company Readily3D — backed by €3.6 million from the European Innovation Fund. 📄 🔗 https://lnkd.in/gzWbMVmj #Bioprinting #3DBioprinting #RegenerativeMedicine #DrugDiscovery #Diabetes #PancreaticResearch #Bioink #LifeSciences #MedTech #TissueEngineering #ENLIGHT #Rousselot #VolumetricBioprinting #PrecisionMedicine #Innovation

Bioengineering of a human iPSC-derived vascularized endocrine pancreas for type 1 diabetes Intrahepatic islet transplantation in patients with type 1 diabetes is limited by donor availability and lack of engraftment. Alternative β cell sources and transplantation sites are needed. We demonstrate the feasibility to repurpose a decellularized lung as an endocrine pancreas for β cell replacement. We bioengineer an induced pluripotent stem cell (iPSC)-based version, fabricating a human iPSC-based vascularized endocrine pancreas (iVEP) using iPSC-derived β cells (iPSC-derived islets [SC-islets]) and endothelial cells (iECs). SC-islets and iECs are aggregated into vascularized iβ spheroids (ViβeSs), and over 7 days of culture, spheroids integrate into the bioengineered vasculature, generating a functional, perfusable human endocrine organ. In vitro, the vascularized extracellular matrix (ECM) sustained SC-islet engraftment and survival with a significantly preserved β cell mass and a physiologic insulin release. In vivo, iVEP restores normoglycemia in diabetic NSG mice. We report a human iVEP providing a controlled in vitro insulin-secreting phenotype and in vivo function. https://lnkd.in/edgaWGYG

Major Diabetes Research Breakthrough: Scientists in China have reported promising results using stem-cell–based therapy aimed at restoring insulin production in patients with Type 1 Diabetes and Type 2 Diabetes. In early-stage clinical studies, researchers were able to generate functional insulin-producing pancreatic cells and transplant them into patients — with some participants reportedly reducing or eliminating their need for external insulin. The therapy works by converting stem cells into pancreatic islet-like cells capable of sensing blood glucose levels and releasing insulin naturally. For Type 1 diabetes — an autoimmune condition where insulin-producing cells are destroyed — this approach aims to biologically replace lost cells. In certain Type 2 cases, restoring insulin production combined with improved metabolic regulation could significantly enhance glucose control. However, experts stress that while results are highly encouraging, large-scale trials, long-term monitoring, and broader regulatory review are still required before calling it a universal “cure.” Stem-cell therapies must demonstrate durability, safety, and affordability at scale. Still, the possibility of restoring the body’s own insulin production marks one of the most exciting developments in diabetes research in decades.